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The diagnosis of latent tuberculosis (TB) infection (LTBI) is critical to improve
TB treatment and control, and the T-SPOT.TB test is a commercial enzyme-linked immunosorbent spot assay used for this purpose. The objective of the study was to increase automation and extend the time between blood collection and processing for the T-SPOT.TB
test from 0 to 8 h to 0 to 54 h. The previous maximum time between blood collection and
processing for the T-SPOT.TB test is 32 h using T-Cell Xtend. For this, we compared the
T-SPOT.TB test using manual peripheral blood mononuclear cell (PBMC) isolation by density
gradient separation at 0 to 8 h (reference method, control arm) to an automated PBMC isolation method using magnetic beads (T-Cell Select kit) at 0 to 55 h postcollection. A total of
620 subjects were enrolled from 4 study sites, and blood samples were collected from each
volunteer, comprising 1,850 paired samples in total. Overall agreement between both methods was 96.8% (conﬁdence interval [CI], 95.9 to 97.6%), with 95.8% (CI, 93.5 to 97.5%)
positive and 97.1% negative agreement (CI, 96.1 to 97.9%). In summary, there was a
strong overall agreement between the automated and manual T-SPOT.TB test processing methods. The results suggest that the T-SPOT.TB test can be processed using automated positive selection with magnetic beads using T-Cell Select to decrease hands-on
time. Also, this cell isolation method allowed for the time between blood collection and
processing to range from 0 to 55 h. Additional studies in larger and diverse patient populations including immunocompromised and pediatric patients are needed.
KEYWORDS ELISPOT, IGRA, T-SPOT.TB, tuberculosis, diagnosis

T

uberculosis (TB) affected nearly 10 million people and killed 1.5 million in 2020 (1).
Improving diagnosis of latent tuberculosis infection (LTBI) is critical to achieve the World
Health Organization (WHO) END-TB targets (2). Approximately one quarter of the world’s
population, including more than 13 million people in the United States, have LTBI (3). Globally,
the WHO recommends LTBI screening for at-risk populations, including children, people living
with HIV, and close contacts of active TB cases, even in high-burden countries (4). The Centers
for Disease Control and Prevention (CDC) recommends LTBI screening in individuals at
increased risk of reactivation to active TB disease, such as close contacts of newly diagnosed
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TB patients, individuals with comorbidities, and those planning to start immunosuppressive
medications such as tumor necrosis factor alpha (TNF-a) blockers or biologics (5). The U.S.
Preventive Services Task Force (USPSTF) recommended screening for LTBI in adults originating from countries with increased TB prevalence regardless of their time in the United
States, as well as those from high-risk congregate settings (6). Interferon gamma release
assays (IGRAs) offer several advantages over tuberculin skin tests (TST) for LTBI screening
(4). Currently, two Food and Drug Administration (FDA)-approved commercial IGRAs are
available: QuantiFERON-TB Gold Plus (QFT, Qiagen Ltd.), which utilizes a whole-blood
enzyme-linked immunosorbent assay (7), and the T-SPOT.TB test (Oxford Immunotec Ltd.,
Abingdon, UK) a modiﬁed enzyme-linked immunosorbent spot (ELISPOT) assay which
measures responses at the single-cell level in peripheral blood mononuclear cells (PBMCs)
(8). ELISPOT testing platforms are limited by a lack of automation, which compromises the
ability of laboratories to scale up testing (9). Increasing automation while allowing the maintenance of ﬂexible times between blood collection and processing would broaden the
availability of the T-SPOT.TB test, especially in settings with limited laboratory capacity. We
aimed to compare the T-SPOT.TB test using PBMCs isolated via manual density gradient
separation performed between 0 and 8 h after blood collection (reference method, control
arm) versus automated positive selection with magnetic beads using the T-Cell Select kit
performed between 0 and 55 h post-blood collection (experimental) (10).

Study design and participant enrollment. We conducted a multicenter, concurrent control, matchedpair study, in which test and control specimens were obtained from each study subject during a single blood
draw. The study was performed over a 6-month period (between November 2019 and March 2020) at four
study sites representing diverse geographic regions and subject populations with various degrees of risk for
LTBI or active TB. Site 1: Cape Town, South Africa (high TB endemicity, 24.5% of sample population); site 2:
Reynosa, Mexico (Mexico-Texas, USA, border; low to intermediate TB endemicity, 6.9% of the sample population);
site 3: Ohio, USA (low to intermediate TB endemicity, 12.9% of the sample population); site 4: Massachusetts, USA
(low TB endemicity, 55.8% of sample population). Fig 1 shows the collection and processing scheme for the
study. The study size was calculated based on recruitment rates at each site, within the predeﬁned study timeline.
However, in total, 616 eligible participants were recruited across all study sites in order to obtain the data
required to investigate concordance between the T-SPOT.TB methodologies. Participants included adults 18 years
or older with either no history of exposure to patients with active pulmonary TB disease (mostly at the low-TB-endemicity site) or having had a close contact with a newly diagnosed TB patient, LTBI, or with present or past TB
disease. Classiﬁcation of LTBI was based on a positive T-SPOT.TB test result using the reference test and no TB
symptoms, while active TB was based on the presence of signs and symptoms of TB, abnormal chest X ray, or culture conﬁrmation when available. Each study site obtained its own institutional review board (IRB) approval: The
Human Sciences Research Council for site 1, the Committee for the Protection of Human Subjects for the
University of Texas Health Science Center at Houston and the Ethics Committee from the Secretaría de Salud de
Tamaulipas for site 2, the WIRB-Copernicus Group (WCG) for The Ohio State University for site 3, and the Advarra
IRB for the New England Center for Clinical Research (NECCR) Primacare Research for site 4. Informed consent
was obtained from all study participants.
T-SPOT.TB testing. Blood samples for each study participant were collected in lithium heparin tubes.
The ﬁrst tube for each study participant was processed within 0 to 8 h from time of collection via density
gradient isolation and tested with the T-SPOT.TB test as indicated by the manufacturer (no T-Cell Xtend
reagent added; reference method, control arm) (9). For the experimental arm, the T-SPOT.TB tests were
performed according to the manufacturer’s instructions between 0 and 55 h (four time blocks of 0 to 8,
18 to 32, 39 to 46, and 48 to 55 h) with cells isolated using the T-Cell Select kit (no T-Cell Xtend used; a brief
description of the T-Cell Select kit is detailed in the supplemental Materials and Methods) (11). Laboratory technicians were blinded to enrollment information for removal of bias. Blood remained in the tubes at room temperature, in temperature-controlled boxes (temperature range, 18 to 25°C) until samples were processed. Spot counting was performed independently by each study site using manual counting with a Universal Serial Bus (USB)
microscope and conﬁrmed again by an automated plate reader by the sponsor (Cellular Technology Ltd., Ohio,
USA), with spot counts compared to capture any discrepancies between methods of reading the count. Any
blood samples that contained fewer than 2.0  106 viable PBMCs per/mL was not run. This is in accordance with
the manufacturer’s instructions that state that the T-SPOT.TB test requires 2.5  105 viable PBMCs per well, and 4
wells are required for each patient sample. A sample which produced in excess of 10 spots in the nil control, or
fewer than 20 spots in the positive control (unless either panel A or panel B is positive, according to a 6-spot cutoff as described below, in which case the result is valid) was considered indeterminate (outside the United States)
or invalid (in the Unites States) and is referred to as indeterminate/invalid here (Table 1). The T-SPOT.TB test
results are interpreted by subtracting the spot count in the nil control well from the spot count in each of the
panels. The test result would be classed as positive if panel A minus the nil control is more than or equal to 6
spots. The test result would be considered negative if both panel A minus the nil control) and (panel B minus the
nil control are less than or equal to 5 spots, including values less than 0. Where the higher of panel A minus the
September 2022 Volume 60 Issue 9

10.1128/jcm.00551-22

2

Downloaded from https://journals.asm.org/journal/jcm on 22 September 2022 by 129.113.53.71.

MATERIALS AND METHODS

Journal of Clinical Microbiology

FIG 1 Testing site structure and sample processing.
nil control and panel B minus the nil control is 5, 6, or 7 spots, the result may be considered borderline. Although
valid, borderline results are considered less reliable than results where the spot count is farther from the cutoff.
Data analysis. Data from the study participants, the specimen history, and spot counts were entered
into a U.S. FDA 21 Code of Federal Regulations (CFR) Part 11-compliant electronic data capture database
(OpenClinica, Massachusetts, USA) and source veriﬁed by the sponsor per the International Conference on
Harmonization/Good Clinical Practice (ICH/GCP) E6 (R2). All analyses were performed using SAS V9. The analysis
comprised data from study participants who had matched experimental versus reference T-SPOT.TB test
results. Data from all study sites were pooled for the main analysis, and supplementary analyses for individual
sites were also performed. The overall agreement between positive and negative specimens was calculated as
positive and negative percent agreement with 95% conﬁdence intervals, or kappa statistic, using as a reference
the 0- to 8-h time point for density gradient centrifugation. For these calculations, the borderline or indeterminate specimens were excluded given that they would have to be repeated in the clinical setting.

RESULTS
A total of 620 study participants were enrolled from the four study sites (Fig. 1). Ages
ranged from 18 to 85 years; 41% were male; 14% had LTBI and 15% had active TB disease
(Table 2 and Table S1 in the supplemental material). Each study participant had specimens
processed at different time points, comprising 1,850 paired samples in total. The overall
agreement between both methods was 96.8% (CI, 95.9 to 97.6%), with 95.8% (CI, 93.5 to
97.5%) positive and 97.1% negative agreement (CI, 96.1 to 97.9%) (kappa 0.853).
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TABLE 1 Summary of inconclusive data, including low PBMC recovery, high negative control (Nil) background, and low responsiveness to the
positive control (PHA), by control and test arms in all study sites
Data [% (n)] for:a
Site no.
Percentage with low PBMC recovery
(cell recovery of ,2.0  106 cells/mL)
for time points
1
2
3
4
All sites

Control

0–8 h

18–32 h

39–46 h

48–55 h

Total (combined time points)

2.6 (4/151)
9.3 (4/43)
0 (0/80)
0.6 (2/346)
1.6 (10/620)

1.3 (2/151)
0 (0/43)
1.3 (1/80)
0 (0/346)
0.5 (3/620)

2.9 (4/139)
0 (0/39)
1.3 (1/80)
0 (0/341)
0.8 (5/599)

NA
0 (0/4)
0 (0/40)
0 (0/154)
0 (0/198)

3.0 (4/133)
2.9 (1/34)
1.7 (1/59)
0.4 (1/273)
1.4 (7/499)

2.4 (14/574)
3.1 (5/163)
0.9 (3/339)
0.2 (3/1,460)
1 (25/2,536)

High nil (.10 spots in nil control well)
1
2
3
4
All sites

2.0 (3/147)
0 (0/39)
0 (0/80)
0.9 (3/344)
1.0 (6/610)

4.1 (6/149)
0 (0/39)
0 (0/79)
0.3 (1/346)
1.1 (7/613)

4.4 (6/135)
0 (0/39)
0 (0/79)
0 (0/341)
1.0 (6/594)

NA
0 (0/4)
0 (0/39)
0 (0/154)
0 (0/197)

3.9 (5/129)
0 (0/33)
0 (0/58)
0 (0/272)
1.0 (5/492)

3.6 (20/560)
0 (0/154)
0 (0/335)
0.3 (4/1,457)
1.0 (24/2,506)

Low PHA (,20 spots in
positive-control well)
1
2
4
5
All sites

0 (0/147)
0 (0/39)
1.3 (1/80)
0.3 (1/344)
0.3 (2/610)

0 (0/149)
0 (0/43)
0 (0/79)
0 (0/346)
0 (0/617)

0 (0/135)
0 (0/39)
1.3 (1/79)
0 (0/341)
0.2 (1/594)

NA
0 (0/4)
0 (0/39)
0 (0/154)
0 (0/197)

0 (0/129)
0 (0/33)
0 (0/58)
0.4 (1/272)
0.2 (1/492)

0 (0/560)
0 (0/158)
0.6 (2/335)
0.1 (2/1,457)
0.2 (4/2,510)

not applicable.

Fig 1 shows the number of study participants (n = 620) and available paired specimens per
study site as follows. For site 1 (Cape Town, South Africa), 151 samples were processed at 0 to
8, 18 to 32, and 48 to 55 h post-blood collection. Site 2 (Mexico) had 43 samples, site 3
(Ohio, USA) had 80 samples, and site 4 (Massachusetts, USA) had 346 samples, tested across
all time points. Where fewer than the total number tested at subsequent time points are
stated, this is due to low PMBC or negative- or positive-control failure resulting in fewer
paired samples being analyzed (Table 1). Furthermore, for purposes of analysis, data from
each individual site were combined for time point analysis, resulting in 595 paired samples
at 0 to 8 h, 577 paired samples at 18 to 32 h, 197 paired samples at 39 to 46 h, and 481
paired samples at 48 to 55 h post-blood collection. The 39- to 46-h time point was not
TABLE 2 Participant characteristics by study site
Data for:
Characteristics
Study site TB endemicity
Study site location
Sample size (n)
No. HIV positive (%)
No. with BCG vaccination (%)

620
42 (7)
317 (51)

Site 1
High
Cape Town, South Africa
151
39 (25)
91 (60)

Site 2
Low to intermediate
Reynosa, Mexico
43
0
37 (86)

Site 3
Low to intermediate
Ohio, USA
80
2 (,1)
16 (20)

Site 4
Low
Massachusetts, USA
346
1 (,1)
173 (50)

Known TB status at the
time of enrollment
No. with no. TB (%)
No. with latent TB infection (%)
No. with active TB disease (%)

443 (71)
87 (14)
90 (15)

11 (7)
51 (34)
89 (59)

6 (14)
36 (84)
1 (2)

80 (100)
0
0

346 (100)
0
0

TB symptoms
No. with cough .2 wks (%)
No. with fever (%)
No. with night sweats (%)
No. with wt Loss (.5 kg) (%)
No. with other (%)
No. with none (%)

101 (16)
31 (5)
86 (14)
63 (10)
39 (6)
498 (80)

95 (63)
30 (20)
84 (56)
60 (40)
50 (33)
38 (25)

2 (5)
1 (2)
0
3 (7)
0
39 (91)

1 (1)
0
0
0
0
79 (99)

3 (,1)
0
2 (,1)
0
0
342 (99)
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TABLE 3 Summary clinical agreements for 0–55 h for each site
Overall agreement [% (n; 95% CI)]
96.9 (1,792/1,850; 96.0–97.6)
94.8 (363/383; 92.1–96.8)
88.7 (102/115; 81.4–93.8)
98.0 (248/253; 95.4–99.4)
98.2 (1,079/1,099; 97.2–98.9)
96.5 (574/595; 94.7–97.8)
96.4 (556/577; 94.5–97.7)
98.0 (193/197; 94.9–99.4)
97.5 (469/481; 95.7–98.7)

Positive agreement with (95% CI)
95.9 (397/414; 93.5–97.6)
98.8 (335/339; 97.0–99.7)
84.9 (45/53; 72.4–93.3)
100 (6/6; 54.1–100.0)
68.8 (11/16; 41.3–89.0
98.0 (145/148; 94.2–99.6)
94.9 (129/136; 89.7–97.9)
50.0 (2/4; 6.8–93.2)
96.0 (121/126; 91.0–98.7)

Negative agreement with (95% CI)
97.1 (1,395/1,436; 96.1–97.9)
63.6 (28/44; 47.8–77.6)
91.9 (57/62; 82.2–97.3)
98.0 (242/247; 95.3–99.3)
98.6 (1,068/1,083; 97.7–99.2)
96.0 (429/447; 93.7–97.6)
96.8 (427/441; 94.7–98.3)
99.0 (191/193; 96.3–99.9)
98.0 (348/355; 96.0–99.2)

performed in the high-risk site (site 1) due to logistics. Table 1 illustrates the number of
specimens and study sites of origin for low PBMC recovery, negative-control failure (high
nil) and positive-control failure (low phytohaemagglutinin [PHA]). Low cell recoveries were
higher in sites 1 and 2 than in other study sites, but overall, low cell recovery rates were 1%
across all study sites and all time points. Indeterminate/invalid rates due to negative-control
failure were slightly elevated in study site 1 compared to the other study sites; however,
the negative-control failure rate was not higher than expected overall. Additionally, there is
no clear indication of any test arm causing a higher rate of negative-control failures compared to the density gradient control arm. Indeterminate/invalid rates due to positive-control failure were very low across all study sites and all control and test arms. The rate of
borderline results was also low across all study sites and control and test arms
(Table S1A). In general, higher borderline rates were observed in the test arm; however, this did not impact the clinical concordance as demonstrated in Table 3 and
Table S1B.
The overall positive and negative agreements with 95% CI for each study site are presented
in Table 3 (kappa range from 0.731 to 0.921). Overall agreement for all sites was higher than
90%, except for study site 2, which recorded 88.7%. This site recruited fewer study participants
overall; therefore, any discordant results have a greater impact on calculated agreements.
Positive agreements ranged between 68.8 and 100.0%, with the latter value being obtained
in site 4, which was a low-risk TB site, with only 6 positive T-SPOT.TB test samples within the
data set. The high-risk TB site recorded a positive agreement of 98.8%, and lower
agreements in the other two sites are representative of lower-risk status associated
with enrollment locations and consequent lower enrollment numbers. Negative
agreements ranged between 63.6% and 98.6% between ﬁeld sites, the latter value
being obtained in the low-risk TB site.
With data pooled from all sites, overall positive and negative values between results of
the T-SPOT.TB test using density gradient and T-Cell Select isolation methods exceeded 95%,
with the exception of positive agreement at the 39 to 46 h time point, which was not performed at the high-risk TB site. The Cochran-Mantel-Haenzel method provides a pooled estimate of the overall agreement by taking a weighted average, the weight for each study
determined by the variability in the agreement estimate for each study. As illustrated in
Table 4, overall and negative agreement values when combined in a weighted manner
exceeded 95%. Positive agreement values all exceed 95%, with the exception of the 39 to
46 h time point.

TABLE 4 Percent agreement using Cochran-Mantel-Haenzel method
Time period (h)
0–8
18–32
39–46
48–55
0–55

Overall agreement (%)
(95% CI)
98.0 (96.6–99.3)
97.2 (95.4–98.9)
99.2 (97.4–100)
98.9 (97.7–100)
97.7 (97.0–98.5)

September 2022 Volume 60 Issue 9

Positive agreement (%)
(95% CI)
99.1 (96.9–100)
97.9 (94.8–100)
50.0 (10.8–100)
98.8 (96.2–100)
98.6 (97.3–99.9)

Negative agreement (%)
(95% CI)
98.4 (96.9–99.9)
97.8 (96.2–99.4)
99.9 (98.7–100)
99.9 (99.2–100)
98.4 (97.7–99.1)
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Site 2 results
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0–8 h (all sites)
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48–55 h (all sites)
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DISCUSSION
The T-SPOT.TB is a commercial IGRA assay that uses an ELISPOT format for the diagnosis
of LTBI. This format requires the separation of PBMCs, which can be an advantage for higher
sensitivity when testing individuals with reduced T cell counts, including immunocompromised individuals (11, 12). However, this step requires manual density gradient centrifugations and careful pipetting technique, which limits the automation of the assay. Here, we
show for the ﬁrst time that the magnetic separation of PBMCs using the T-Cell Select kit,
increases automation of the T-SPOT.TB test assay without compromising performance.
Testing was conducted in participants from four study sites with diverse population
characteristics, including differences in the prevalence of latent TB infection and disease. Furthermore, we found that using the T-Cell Select protocol, the time between
blood collection and initiation of specimen processing could be delayed by up to
55 h, without addition of the T-Cell Xtend reagent. All of this was in contrast to the 0to 8-h reference standard. During the 55-h period, the blood specimens were kept at
room temperature (range, 18 to 25°C), with no need for refrigeration.
A potential concern when testing the T-Cell Select kit was the possibility of an increasing
proportion of inconclusive results (e.g., low PBMC counts or indeterminate/invalid) due to a
hold period for up to 55 h prior to blood processing, combined with the positive selection
of cells. However, compared to the control arm, we did not ﬁnd a signiﬁcant increase in the
proportion of low PBMC recoveries, high background with the nil results, or lack of responsiveness to the positive control with PHA (Table 1). We did observe a higher proportion of
low cell recoveries and indeterminates/invalids at site 1 and low cell counts at site 2, which
may be inﬂated by their smaller sample size. The number of indeterminates/invalids due to
a failed response to PHA was very low overall at all sites and equated to just 4 samples in
the entire data set. Therefore, it can be concluded that cell isolation using the T-Cell Select
kit, with blood storage of up to 55 h has no signiﬁcant impact on cell recovery rate or indeterminate/invalid rate. It is worth noting that our study is the ﬁrst to use an automated platform for a diagnostic assay using an ELISPOT format, and while our approach is described
for TB, it can be adapted for use with other pathogens.
As mentioned brieﬂy in the Results section, several sites and time points were observed
to have lower overall agreement in results. For example, study site 2 was observed to have
a lower overall agreement of 88.7%, but as this site recruited fewer subjects overall, any
discordant results had a greater impact on calculated agreements. Further, site 1 recorded
a negative agreement of 63.6%, but this low negative agreement value is as expected for
an area of high TB endemicity where many individuals may have been exposed to TB
unknowingly. Finally, while the positive agreement values overall were in excess of 95%,
the 39 to 46 h time point recorded a positive agreement of 50%. However, fewer subjects were enrolled in this cohort (n = 4), as site 2 was not designated a high-risk site;
therefore, any discordant results had a larger impact on the percent agreement.
We recognize the potential study limitations, largely that this study was focused on the
performance of the T-Cell Select kit compared to the standard density gradient centrifugation, and hence, only basic clinical information was gathered from the study participants.
Therefore, we did not expand the analysis to interpret the data in the context of the clinical
ﬁndings, including immunocompromised individuals. However, given the high concordance
between assays, we do not anticipate any differences in performance between intermediate/high- and low-risk TB study sites. Additionally, this study was designed for analysis when
high-, intermediate-, and low-TB risk sites were combined. In future studies it will be important to further investigate the performance of the T-Cell Select kit within sites with similar TB
risk, particularly those with high endemicity for TB, where there will be high proportions of
positive results.
Conclusions. There was a strong overall concordance between the automated and
manual way of isolating cells for use in the T-SPOT.TB test. The T-SPOT.TB test can be processed using automated positive selection with T-Cell Select to decrease technician hands-on
time. T-Cell Select allows for blood samples to be stored for 0 to 55 h compared to 32 h in
the past, when using T-Cell Xtend.
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